TTrialPathMatch Me to Trials
← Back to trials
RecruitingOpen Angle GlaucomaPigmentary GlaucomaPseudoexfoliation Glaucoma

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

Sponsor: Jonathon Myers

You may qualify if…

  • Moderate to severe open angle glaucoma (including POAG, PG, and PXG)
  • Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9
  • Visual acuity HM or better
  • VF MD -6dB or worse
  • Failed medical therapy and/or laser treatment
  • Incisional glaucoma surgery contemplated as next intervention
  • Phakic or pseudophakic

You may not qualify if…

  • Traumatic, uveitic, neovascular glaucoma, or angle closure glaucoma
  • Previous incisional glaucoma surgery
  • ALT; History of iridotomy, SLT, or micropulse laser trabeculoplasty within the prior 90 days
  • Active ocular inflammation or edema, clinically significant corneal dystrophy
  • Corneal or other pathology preventing accurate Goldmann applanation tonometry

Where it's recruiting

Pennsylvania

Philadelphia

Source: ClinicalTrials.gov · NCT07228221 · last updated 2025-11-14

Standalone iStent Infinite and iDose TR for Management of Moderate to · TrialPath